Fig. 2From: Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancerBest evidence sources from modeling studies. One of the modeling studies used life-years gained as an outcome measure; therefore, it did not have a source for utilityBack to article page